Immatics (IMTX) Share-based Compensation (2019 - 2025)
Immatics (IMTX) posted Share-based Compensation of $3.8 million for Q4 2025, up 1.48% sequentially from $3.8 million in Q3 2025, and down 20.57% YoY from $4.8 million in Q4 2024.
Immatics (IMTX) Share-based Compensation (2019 - 2025) Analysis & Trends
Immatics has reported Share-based Compensation for 7 years, with the latest figure at $3.8 million in Q4 2025.
- Quarterly Share-based Compensation fell 20.57% year-over-year to $3.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $16.9 million (down 11.63% YoY) and the FY2025 annual result came in at $17.0 million, down 11.16% from the prior year.
- Share-based Compensation rose to $3.8 million in Q4 2025 per IMTX's latest filing, from $3.8 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $10.0 million in Q1 2021 and troughed at -$17.5 million in Q4 2023.
- A 5-year average of $4.6 million and a median of $5.3 million in 2021 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2021 and 2023: Share-based Compensation surged 108769.42% in 2021, then plunged 393.7% in 2023.
- Over 5 years, Share-based Compensation stood at $5.4 million in 2021, then advanced by 10.16% to $6.0 million in 2022, then slumped by 393.7% to -$17.5 million in 2023, then soared by 127.64% to $4.8 million in 2024, then retreated by 20.57% to $3.8 million in 2025.
- According to Business Quant data, Share-based Compensation over the past three periods registered $3.8 million, $3.8 million, and $4.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Immatics | 1.27 Bn | 719.31 Mn | - | 17.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.84 Mn |
| Dec 31, 2025 | 3.84 Mn |
| Sep 30, 2025 | 3.79 Mn |
| Sep 30, 2025 | 3.79 Mn |
| Jun 30, 2025 | 4.69 Mn |
| Jun 30, 2025 | 4.69 Mn |
| Mar 31, 2025 | 4.55 Mn |
| Mar 31, 2025 | 4.55 Mn |
| Dec 31, 2024 | 4.84 Mn |
| Dec 31, 2024 | 4.84 Mn |
| Sep 30, 2024 | 4.95 Mn |
| Sep 30, 2024 | 4.95 Mn |
| Jun 30, 2024 | 4.64 Mn |
| Jun 30, 2024 | 4.64 Mn |
| Mar 31, 2024 | 4.67 Mn |
| Mar 31, 2024 | 4.67 Mn |
| Dec 31, 2023 | -17.51 Mn |
| Dec 31, 2023 | -17.51 Mn |
| Sep 30, 2023 | 5.10 Mn |
| Sep 30, 2023 | 5.10 Mn |